MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Addresses Significant International Market With Generx 0 comments
    Sep 28, 2012 2:54 PM | about stocks: CXM

    Cardium Therapeutics' Generx product candidate is a good example of the company's strategy of acquiring and developing new and innovative bio-medical product opportunities addressing unmet medical needs on a worldwide basis.

    Generx (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic for patients with advanced coronary artery disease. Basically, it stimulates the growth of supplemental collateral blood vessels in the heart, which enhances myocardial blood flow in heart patients. It involves a one-time intracoronary administration, using a standard cardiac infusion catheter, making it simple and cost effective to use. Unlike standard therapies for the heart, like nitrates and beta blockers that only provide transient relief of symptoms, Generx is a disease-modifying regenerative medicine that can result in structural and physiologic changes in the heart, specifically the growing of new blood vessels. It is being designed as a superior alternative for patients without access to or ability to pay for more costly and invasive surgical procedures to increase blood flow, a common problem in many countries with a less developed healthcare system. As such, Generx is currently being developed for international markets.

    Generx has already been tested in clinical studies at more than one hundred medical centers in the U.S., Europe, and elsewhere, and is now part of a study in the Russia to evaluate its therapeutic effects on patients with myocardial ischemia due to coronary artery disease. The ASPIRE Phase 3 registration study is a controlled multi-center study conducted at up to eight leading cardiology centers in the Russian Federation, where the efficacy of Generx will be measured using rest and stress SPECT (Single-Photon Emission Computed Tomography) myocardial imaging to sensitively measure improvements in microvascular cardiac perfusion.

    In addition to Generx and other products, the Cardium portfolio includes Excellagen, a new, FDA-cleared highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management for use with diabetic and other ulcers, surgical and other wounds, as well as burns.

    For additional information, visit www.CardiumTHX.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.